Colorectal neoplasm

There are 41 papers on colorectal neoplasm in aging research: 3 trials and 26 observational studies in people, 1 in animals, 9 reviews.

Disease

41 papers study it8 more mention it22 findings

MeSH

3 new papers in 30 daysSee all 49 papers on colorectal neoplasm

“In CHARLS, fully adjusted models showed strong associations for TyG (OR = 3.98, 95% CI: 2.66–5.94)”
Investigation of TyG-based metabolic indices and colorectal tumor risk: Evidence from the CHARLS and NHANES cohortsResearch Square2026doi:10.21203/rs.3.rs-11048680/v1
  • Human trial3
  • Humans26
  • Animals1
  • In silico2

Upstream

4

25-hydroxyvitamin D

no changein humans1

1 study
  1. 25-hydroxyvitamin D was not clearly linked with colorectal neoplasm in humans (Lynch syndrome carriers).

    HumansLynch syndrome carriers

More on 25-hydroxyvitamin D

LEP

no changein humans1

1 study
  1. LEP was not clearly linked with colorectal neoplasm in humans (fully adjusted model) (IRR: 0.95).

    Humansfully adjusted modeln = 602

More on LEP

Metabolic syndrome

no changein humans1

1 study
  1. Metabolic syndrome was not clearly linked with colorectal neoplasm in humans (fully adjusted model) (IRR: 1.06; 95% CI, 0.83-1.36).

    Humansfully adjusted modeln = 4,891

More on Metabolic syndrome

Obstructive sleep apnea

no changein humans1

1 study
  1. Obstructive sleep apnea was not clearly linked with colorectal neoplasm in humans.

    Humansn = 335

More on Obstructive sleep apnea

Associations

17

Age

upin humans2OR 1.061

2 studies
  1. Age is associated with colorectal neoplasm in humans (Population at high risk for colorectal tumors) (OR 1.061, 95% CI 1.038–1.083).

    HumansPopulation at high risk for colorectal tumors

  2. Age is linked with a higher risk of colorectal neoplasm in humans (fully adjusted model) (IRR: 1.73 per decade; 95% CI, 1.53-1.95).

    Humansfully adjusted modeln = 4,891

IMCS LR model

upin humans1

1 study
  1. IMCS LR model predicts colorectal neoplasm in humans (Validation set) (Validation-set AUC 0.690, 95% CI 0.644–0.736).

    HumansValidation set

More on IMCS LR model

IMCS XGBoost model

upin humans1

1 study
  1. IMCS XGBoost model predicts colorectal neoplasm in humans (Training set) (Training-set AUC 0.817, 95% CI 0.794–0.841).

    HumansTraining set

More on IMCS XGBoost model

PSQI score

upin humans1OR 1.512

1 study
  1. PSQI score is associated with colorectal neoplasm in humans (Population at high risk for colorectal tumors) (OR 1.512, 95% CI 1.003–2.279).

    HumansPopulation at high risk for colorectal tumors

More on PSQI score

TyG-related indices

mixedin humans1

1 study
  1. TyG-related indices predict colorectal neoplasm in humans (ROC analyses in CHARLS and NHANES) (AUCs 0.767–0.786 in CHARLS; 0.570–0.587 in NHANES).

    HumansROC analyses in CHARLS and NHANES

More on TyG-related indices

TyG-WWI

upin humans1OR 1.08

1 study
  1. TyG-WWI is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 1.08, 95% CI 1.06–1.11).

    HumansCHARLS; fully adjusted logistic regressionn = 9,293

More on TyG-WWI

TyG-HGB

upin humans1OR 1.28

1 study
  1. TyG-HGB is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 1.28, 95% CI 1.20–1.36).

    HumansCHARLS; fully adjusted logistic regressionn = 9,293

More on TyG-HGB

TyG-CI

upin humans1OR 2

1 study
  1. TyG-CI is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 2.00, 95% CI 1.60–2.50).

    HumansCHARLS; fully adjusted logistic regressionn = 9,293

More on TyG-CI

Triglyceride-glucose index

upin humans1OR 3.98

1 study
  1. Triglyceride-glucose index is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 3.98, 95% CI 2.66–5.94).

    HumansCHARLS; fully adjusted logistic regressionn = 9,293

More on Triglyceride-glucose index

Multitarget stool DNA

upin humans1

1 study
  1. Multitarget stool DNA predicts colorectal neoplasm in samples completing both tests (100.0% - 43.0% and 53.3% - 27.2%).

    Reviewin samples completing both tests

More on Multitarget stool DNA

All 17

Trial sponsors

Funding

5 grants since 2018

National Cancer Institute$3.3M

Latest

Dec 2025: 0Jan 2026: 5Feb 2026: 3Mar 2026: 5Apr 2026: 0May 2026: 0Jun 2026: 2Jul 2026: 3Aug 2026: 5Sep 2026: 7Oct 2026: 3Nov 2026: 235 papers in 12 months

See all 49 papers on colorectal neoplasm